Vitamin D Management
Evaluation and Monitoring
- When evaluating vitamin D levels, measure both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D to assess vitamin D metabolism in patients with Ehlers-Danlos Syndrome (EDS) 1
- Check serum calcium and phosphorus levels to assess for hypercalcemia in EDS patients with elevated vitamin D levels, and monitor every 2-4 weeks 2
- The American Journal of Kidney Diseases recommends measuring serum calcium and phosphorus every 3 months during vitamin D treatment 3
- Recheck 25-hydroxyvitamin D level after completion of initial therapy (8-12 weeks) 3
- Monitor PTH levels to assess for normalization 3
Treatment and Management
- For EDS patients with vitamin D deficiency (<20 ng/mL), initial therapy should consist of ergocalciferol (vitamin D2) 50,000 IU orally once weekly for 8-12 weeks, as recommended by the American Journal of Kidney Diseases 3, 4
- Target a serum 25-OH vitamin D level of 30-40 ng/mL in EDS patients 5
- Once vitamin D levels normalize (>30 ng/mL), transition to maintenance therapy with daily vitamin D3 (cholecalciferol) 800-2,000 IU per day or continue with monthly ergocalciferol 50,000 IU 3, 4
- If supplementation is clinically indicated in EDS patients, restart at 50% of previous dose once vitamin D levels normalize, and consider using lower maintenance doses (400-800 IU daily) rather than high-dose regimens 6
Special Considerations
- EDS patients may have altered vitamin D metabolism, similar to patients with CYP24A1 mutations, which should be considered in vitamin D management 1
- Vitamin D deficiency can lead to secondary hyperparathyroidism, and monitoring for this condition is essential 3
- Consider primary hyperparathyroidism if PTH remains elevated despite normalization of vitamin D levels or if hypercalcemia develops during vitamin D supplementation 7
- Be aware of the potential for hypercalcemia (symptoms: nausea, vomiting, constipation, confusion) and take action if serum calcium exceeds 10.2 mg/dL or serum phosphorus exceeds 4.6 mg/dL 3, 4
- Annual reassessment of 25-hydroxyvitamin D levels is recommended to ensure adequate treatment and prevent complications associated with vitamin D deficiency and secondary hyperparathyroidism 3